OR WAIT null SECS
Single-use systems hold key benefits for biomanufacturers, despite certain limitations.
Efforts to optimize the ideal blend of technology and best practices that are needed to protect and deliver time- and temperature-sensitive biologic therapies, vaccines, and cell and gene therapies continue to evolve.
Digitalization of bioprocessing is slowly bringing benefits to the biopharma industry.
March 21, 2023
Sartorius BIA Separations and Teknova will collaborate to combine their technologies in an effort to streamline the downstream purification process.
Samsung Biologics plans to invest more than ₩1.9 trillion (US$1.5 billion) in the new Incheon, South Korea, facility, which will hold a manufacturing capacity of 180,000 L.
March 17, 2023
Sandoz, a Novartis division, is expected to invest at least $400 million to build a new biologics manufacturing facility in Lendava, Slovenia, to support growing demand for biosimilars.
Under a technology licensing agreement with Bhami Research Laboratory, Catalent intends to develop formulations that will allow for the delivery of high-concentration biologics subcutaneously.
March 10, 2023
Webinar Date/Time: Wednesday, March 29th 2023 7am PDT | 10am EST | 4pm CEST
March 09, 2023
Catalent is expanding its UpTempo AAV platform to accelerate the development of gene therapies.
March 03, 2023
Webinar Date/Time: Tue, Apr 11, 2023 11:00 AM EDT
March 02, 2023
Process and plasmid design optimization, disposable equipment, and flexible platform processes all play important roles.
Decreasing vein to vein time saves lives.
March 01, 2023
There is growing pressure for robust and economically scalable viral-vector manufacturing technologies.